INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

Publication of detailed analysis on INKmune biology compared to cytokine stimulated cells demonstrates important anti-tumor memory like NK cell characteristics

BOCA RATON, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced the publication of our landmark paper in Journal Immunotherapy of Cancer co-authored by Mark Lowdell, PhD, INmune’s Chief Scientific Officer, titled,  “ Proteomic and phenotypic characteristics of memory-like Natural Killer cells for cancer immunotherapy.” Link to paper: https://jitc.bmj.com/content/12/7/e008717